New combo aims to outsmart prostate cancer without Long-Term hormone shots
NCT ID NCT03007732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) — alone or with an injected immune stimulant called SD-101 — to standard radiation and short-term hormone therapy could better control prostate cancer that has spread to a few spots. Twenty-three men with newly diagnosed, hormone-sensitive prostate cancer took part. The goal was to see if the combination could keep PSA levels low even after hormone therapy was stopped, potentially allowing men to avoid continuous hormone treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and SD-101 (a drug injected into the tumor to boost immune response)
What this could lead to
If successful, this combination could offer a new way to control prostate cancer that has spread to a few spots, potentially delaying the need for continuous hormone therapy.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The added drugs can cause immune-related side effects, and the benefit over standard care is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California San Francisco
San Francisco, California, 94143, United States